EUS & ERCP Monthly — September 2026 (Vol 1, Issue 8)

EUS & ERCP MONTHLY
UKIEUS — Education & Media Series · www.ukieus.co.uk
Vol. 1, Issue 8 · September 2026 · Editor: Dr Venkat Mahesh, MRCP, FEBGH

From the editor — September 2026

September’s literature is a month of null results and a landmark guideline. ESGE has published its new Biliary Stricture Management guideline: 13 recommendations that make EUS guided drainage the next step after failed ERCP in malignant obstruction and set a liver-volume target for hilar drainage. Two randomised trials then found nothing to choose between the techniques tested: heparin wet suction against conventional suction for EUS-FNB, and 0.025-inch against 0.035-inch guidewires for primary cannulation. A 25-centre Italian registry shows that in high-risk pancreatic cancer surveillance a new cyst follows age more closely than germline gene, and a crossover reader study shows AI helping novice endosonographers on stored images. UK authors from UCLH and the Ulster Hospital contributed to the ESGE guideline. From 402 papers harvested, five are featured and eleven listed.

— Dr Venkat Mahesh, MRCP, FEBGH · Education & Media Lead, UKIEUS

TOP 5 FEATURED PAPERS — SEPTEMBER 2026

RANKED #1 Score 79/100 (+5 UK) · ESGE evidence-based guideline · ERCP / EUS-BD · UK AUTHOR SPOTLIGHT

ESGE’s new biliary stricture guideline makes EUS-guided drainage the next step after failed ERCP, and sets a liver-volume target for hilar drainage

Lemmers A, … Johnson G, … Tham TC, … Triantafyllou K · ESGE Guideline, 13 recommendations · UCLH, Ulster Hospital Belfast and European centres · Endoscopy 2026;58(11):1310–1344 · DOI 10.1055/a-2921-6492 · PMID 42692059

Guideline position: this is the current ESGE position on stenting. Tissue sampling sits elsewhere: the companion ESGE diagnostic work-up guideline (Facciorusso et al., Endoscopy 2025) covers sampling, and ASGE (Fujii-Lau et al., Gastrointest Endosc 2023) has separate guidance for strictures of undetermined aetiology. The ASGE 2024 therapeutic-EUS guideline (Pawa et al., Gastrointest Endosc 2024;100:967–979, PMID 39078360) takes EUS-BD versus PTBD after failed ERCP as its first question, and the ACG 2023 guideline (Elmunzer et al., Am J Gastroenterol 2023;118:405–426, PMID 36863037) covers drainage of extrahepatic and perihilar strictures.

Of the 13 recommendations in the abstract, five are worded “recommends” and eight “suggests”. In benign disease, ESGE suggests multiple plastic stents for post-cholecystectomy strictures (a fully covered SEMS can be considered if the stricture is more than 2 cm below the hilar confluence or the patient will not tolerate repeat ERCP), balloon dilation alone for high-grade PSC strictures, and avoiding uncovered SEMS when the aetiology is unconfirmed.

In distal malignant obstruction it recommends a 10-mm SEMS for preoperative and neoadjuvant drainage, and endoscopic over surgical or percutaneous drainage for inoperable disease. In hilar disease it recommends ERCP over PTBD for preoperative drainage; for palliation in Bismuth III–IV it prefers ERCP, or ERCP plus EUS-BD, over primary PTBD, aiming to drain more than 50%, ideally 70% or more, of viable liver volume. Either plastic stents or uncovered SEMS are acceptable for palliative hilar drainage, with plastic preferred when the strategy is undecided.

After failed or unfeasible ERCP, ESGE recommends EUS-BD over PTBD. For distal strictures it suggests hepaticogastrostomy where a duodenal stricture is present, and either hepaticogastrostomy or choledochoduodenostomy where it is not. PTBD is the fallback when EUS-BD fails.

What sits behind the EUS-BD preference. The comparative evidence is mostly observational. A 2023 meta-analysis of 24 studies (Giri et al., Surg Laparosc Endosc Percutan Tech 2023;33:411–419, PMID 37314182) found similar technical success, higher clinical success (OR 2.55), fewer adverse events (OR 0.41) and fewer reinterventions (OR 0.20) with EUS-BD. An earlier meta-analysis in malignant obstruction (Wang et al., J Laparoendosc Adv Surg Tech A 2022;32:747–755, PMID 34677099; 9 studies, 469 patients) found the clinical-success advantage disappeared when both arms used metal stents (OR 0.36, 95% CI 0.06–2.00), which suggests unequal stent strategies explain part of the gap.

The newest prospective comparison is PUMa (Schmitz et al., Endoscopy 2026;58:858–871, PMID 42128368): 209 patients with unresectable distal obstruction in 14 European centres, non-randomised and propensity-matched, with metal stents in both arms. PTBD could not be shown non-inferior on technical success (91.2% vs 97.1%). EUS-BD had better intention-to-treat clinical success (73.5% vs 55.9%, P = 0.05) and fewer 30-day reinterventions, driven mainly by choledochoduodenostomy. Adverse events (16.7% vs 14.5%), six-month reintervention and survival did not differ. A single-centre cohort of 101 patients pointed the other way on safety (Ciesielski et al., Cancers 2026;18:783, PMID 41827717): any complication 29.7% vs 12.5% and major complications 10.8% vs 0% with EUS-BD. Allocation followed operational availability, and survival favoured EUS-BD (median 143 vs 54 days), so confounding is likely in both directions.

The hilar target. The liver-volume threshold rests on retrospective volumetry, not trials. In a 107-patient Paris cohort (Vienne et al., Gastrointest Endosc 2010;72:728–735, PMID 20883850), draining more than 50% of liver volume predicted effective drainage (OR 4.5) and longer median survival (119 vs 59 days), while stenting an atrophic sector raised the risk of cholangitis (OR 3.04). The ASGE hilar guideline (Qumseya et al., Gastrointest Endosc 2021;94:222–234, PMID 34023067) suggests either percutaneous or endoscopic palliative drainage, with the choice based on patient preference, disease and local expertise.

Clinical bottom line: Where ERCP fails in malignant biliary obstruction, EUS-BD is now the guideline-preferred next step ahead of PTBD, which makes local EUS-BD capability a service question. The comparative evidence is modest and partly observational, and one recent cohort found more complications with EUS-BD, so local expertise and patient fitness still shape the choice. For hilar disease the target is volume of liver drained, not the number of stents.

Primary literature identified via PubMed systematic search. Broader clinical context, including identification of contemporaneous trials, meta-analyses, and guideline positions, verified through structured evidence synthesis. All references independently confirmed via PubMed prior to inclusion.

RANKED #2 Score 69/100 · Multicentre registry cohort · pancreatic cyst surveillance

In high-risk pancreatic cancer surveillance, a new cyst follows age more closely than germline gene, and short-term progression is rare

Dall’Olio et al. · 25 Italian centres, 2016–2025 · n=1,688 · JAMA Netw Open 2026;9(9):e2635610 · DOI 10.1001/jamanetworkopen.2026.35610 · PMID 42776526

Guideline position: not directly tested. The AGA 2020 clinical practice update on pancreatic cancer screening in high-risk individuals (Aslanian et al., Gastroenterology 2020;159:358–362, PMID 32416142) prefers MRI and EUS in combination, with 12-month intervals when no concerning lesion is present and shorter intervals for indeterminate or high-risk lesions. The CAPS consensus (Goggins et al., Gut 2020;69:7–17, PMID 31672839) also prefers EUS and MRI/MRCP, recommends annual surveillance without concerning lesions, and asks for surveillance in a research setting at expert centres. The Kyoto IPMN guideline (Pancreatology 2024) allows surveillance to stop or continue after five stable years. This cohort reports cyst incidence, not outcomes by interval, so it neither confirms nor challenges any of them.

Among 1,688 high-risk individuals under MRCP and/or EUS surveillance, 496 (29.4%) had a presumed IPMN. Of 1,298 without a baseline cyst, 124 (9.6%) developed one. Compared with familial pancreatic cancer, no germline pathogenic-variant group had significantly different incidence (PGV1 adjusted hazard ratio 1.82, 95% CI 0.97 to 3.43; PGV2 0.81; PGV3 0.70). Older age raised incidence (1.04 per year). Cyst growth and duct trajectories did not differ across groups, and 13 patients (2.6%) progressed to worrisome features or high-risk stigmata.

The fit with earlier cohorts is reasonable. Canto et al. (Gastroenterology 2018; 354 individuals, median 5.6 years) saw 24 (7%) progress to cancer or high-grade dysplasia, about 1.6% a year, with 93% having worrisome features first. Overbeek et al. (Gastroenterology 2022;162:772–785, PMID 34678218; 2,552 individuals, median 29 months) saw 28 (1%) progress; 12 had a previously growing cyst (median 5 mm a year) and 46% presented with a new lesion.

The Dutch data lean the other way on genotype. Overbeek et al. (Clin Gastroenterol Hepatol 2024;22:62–71, PMID 37031711) followed 457 high-risk individuals for a median 48 months: cumulative IPMN incidence was 46%, IPMNs grew faster than in 442 sporadic-IPMN controls (≥2.5 mm a year in 31% vs 7%), and neoplastic progression occurred in 3 pathogenic-variant carriers with an IPMN (11%) against 6 controls (1%) and in none of the variant-negative familial kindreds. An earlier three-year report from the Italian registry itself (Paiella et al., Am J Gastroenterol 2024;119:739–747, PMID 37787643) found 8 pancreatic cancers and one PanIN3 among 156 people with at least three years of follow-up or an event, five of the eight cancers in variant carriers. The new Italian result therefore does not contradict a gene-specific signal; at a median 17 months it cannot yet see one.

Three limits matter. The PGV1 interval includes 1, so a signal for that group is neither shown nor excluded. IPMN is presumed on imaging, without histology. And median follow-up was 17 months (IQR 0 to 36), too short to say anything about gene-specific long-term risk.

Clinical bottom line: In surveillance, a new cyst tracks age more than gene. Short-term progression was rare, but at a median 17 months of follow-up this does not settle gene-specific long-term risk or justify changing surveillance intervals.

Primary literature identified via PubMed systematic search. Broader clinical context, including identification of contemporaneous trials, meta-analyses, and guideline positions, verified through structured evidence synthesis. All references independently confirmed via PubMed prior to inclusion.

RANKED #3 Score 66/100 · Multicentre randomised crossover trial · EUS tissue acquisition

Heparin wet suction does not improve EUS-FNB diagnostic yield over conventional suction; a second pass adds more than a change of technique

Chon et al. · Multicentre, South Korea · 174 randomised, 170 analysed · J Gastroenterol Hepatol 2026 · DOI 10.1111/jgh.70759 · PMID 42764150

Guideline position: consistent, but silent on wet suction in the abstracts. The 2025 ESGE Technical and Technology Review (Facciorusso et al., Endoscopy 2025;57:390–418, PMID 40015316) updates the 2017 guidance and recommends end-cutting FNB needles over reverse-bevel FNB or FNA needles for solid pancreatic lesions. Its PubMed abstract does not state a suction recommendation, so none is quoted. The 2017 guidance pre-dated the modern FNB trials.

Each patient had one pass with heparin wet suction and one with conventional suction, using a 22G FNB needle. Diagnostic yield was 82.9% vs 83.5% (paired difference −0.6 points, 95% CI −6.7 to 5.5). Technical success was 100% in both. Immunohistochemistry adequacy was 80.6% vs 78.8%. One self-limiting bleed occurred with conventional suction. Combined yield after both passes was 91.2%, which the authors themselves say needs validation.

The trial agrees with the wider evidence on FNB needles. Facciorusso et al. (Gastrointest Endosc 2023;97:839–848, PMID 36657607; 9 RCTs, 756 patients) ranked modified wet suction best for specimen adequacy and integrity. Crinò et al. (Endoscopy 2023;55:225–234, PMID 35915956; 210 patients) found more tissue cores with wet suction than slow-pull (71.4% vs 61.4%) with similar accuracy. A 2026 meta-analysis (Huang et al., Ther Adv Gastroenterol 2026;19, PMID 42369614; 7 RCTs, 784 patients) found overall accuracy similar (RR 1.025) with the gain appearing in the FNA subgroup. Taken together, the advantage of wet suction is clearest for tissue quality and blood contamination, and the accuracy gain in the 2026 analysis sat in the FNA subgroup.

A closer randomised comparator. A 200-patient multicentre non-inferiority RCT of dry versus wet suction (Xu et al., Am J Gastroenterol 2025;120:2529–2537, PMID 40019152) found diagnostic accuracy of 97.9% vs 96.9% (difference 1.0 point, 95% CI −3.5 to 5.5), with no difference in adequacy or blood contamination, and more procedural steps with wet suction. A single pass gave accuracy above 90% without on-site evaluation. That sits alongside pooled pass data from 19 RCTs (Chalhoub et al., Gastrointest Endosc 2024;100:595–604, PMID 38852683): with Franseen or fork-tip needles a second pass improved accuracy (OR 1.80), while a third improved adequacy but not accuracy. My reading is that one pass can suffice in some units, a second pass is where accuracy gains sit with current needles, and a third mainly protects tissue for ancillary testing.

Limits: a crossover design takes the same lesion twice, so sequence and carry-over effects deserve attention, and the 91.2% combined yield is a secondary observation. The conclusion that wet suction adds nothing with an FNB needle is my reading of how these results fit together, not a stated finding of the meta-analyses.

Clinical bottom line: With a modern FNB needle, heparin wet suction adds nothing to diagnostic yield over conventional suction. A second pass raises cumulative yield more than changing the suction method does.

Primary literature identified via PubMed systematic search. Broader clinical context, including identification of contemporaneous trials, meta-analyses, and guideline positions, verified through structured evidence synthesis. All references independently confirmed via PubMed prior to inclusion.

RANKED #4 Score 64/100 · Randomised crossover reader study · AI-assisted EUS

AI overlay helped novice endosonographers detect solid pancreatic lesions on stored images, but it has not been tested on live scanning

Fujisawa et al. · Six Japanese centres · 8 endosonographers, 118 patients’ image sets · Dig Endosc 2026;38(9):e70282 · DOI 10.1111/den.70282 · PMID 42720264

Guideline position: no EUS-specific recommendation identified. ESGE’s 2022 position statement on the expected value of AI (Messmann et al., Endoscopy 2022;54:1211–1231, PMID 36270318) sets acceptance thresholds for upper GI completeness, Barrett’s neoplasia, gastric precancer, capsule endoscopy and colorectal polyps; EUS is not among them. ESGE’s 2025 curriculum statement (Mori et al., Endoscopy 2026;58:202–210, PMID 41338282) asks for basic competence before adopting AI, awareness of cognitive bias and avoidance of over-reliance.

Two deep-learning models were tested: one for solid pancreatic lesion detection, one for parenchyma recognition. Eight endosonographers (five novices, three experts) read 120 lesion image sets and 160 parenchyma image sets in a randomised two-period crossover. Among novices, AI assistance raised detection sensitivity from 76.8% to 88.7% (p < 0.001) and accuracy from 78.7% to 86.4%, and specificity met the non-inferiority criterion (84.2% vs 80.5%). Expert sensitivity was maintained. Parenchyma recognition sensitivity rose from 83.3% to 86.3% but did not meet the superiority criterion (p = 0.095).

Where this sits. Randomised evidence now exists at three levels, and only the first is live. Station recognition: in a 290-patient single-centre RCT (Wu et al., Lancet Digit Health 2023;5:e812–e820, PMID 37775472), an AI prompt cut missed scanning stations from 14.3% to 4.5%, a quality endpoint rather than lesion detection. Real-time lesion detection: in 308 patients scanned concurrently by two blinded experts (Bang et al., Endoscopy 2026;58:223–232, PMID 40953587), AI-EUS detected 97.1% of solid masses against 100% for conventional EUS (risk difference 2.9%, 95% CI −1.2 to 6.8), so comparable rather than better, and in experts only. Stored images or video: Cui et al. (JAMA Netw Open 2024;7:e2422454, PMID 39028670; 12 endoscopists, 130 patients) raised novice accuracy from 0.69 to 0.90 with a multimodal model, and Montanelli et al. (Endoscopy 2026;58:1093–1101, PMID 42617651; 57 endosonographers) raised accuracy from 70.8% to 77.1%, mainly for small or briefly visible lesions, with no significant difference in effect by experience level.

The direction is consistent across the reader studies, which strengthens the case that AI helps less-experienced readers detect solid lesions, but none shows that it changes diagnosis or management in practice. A 2026 review (Kuwahara et al., Dig Endosc 2026;38(6):e70171, PMID 42227807) notes that most EUS-AI models are single-institution and internally validated, which may overestimate real performance, and that only one model has been approved, in Japan, with unpublished technical details.

Clinical bottom line: AI overlay helps novices find solid pancreatic lesions on stored images. It has not been tested on live scanning by novices or on patient outcomes, so treat it as a training and adjunct signal.

Primary literature identified via PubMed systematic search. Broader clinical context, including identification of contemporaneous trials, meta-analyses, and guideline positions, verified through structured evidence synthesis. All references independently confirmed via PubMed prior to inclusion.

RANKED #5 Score 64/100 · Single-centre randomised non-inferiority trial · ERCP cannulation

Guidewire calibre does not change primary biliary cannulation success: 0.025-inch matched 0.035-inch in a 130-patient RCT

Waldthaler et al. · Karolinska, Stockholm · n=130 · Scand J Gastroenterol 2026 · DOI 10.1080/00365521.2026.2727533 · PMID 42713787

Guideline position: consistent, silent on calibre. ESGE (Testoni et al., Endoscopy 2016) recommends the guidewire-assisted technique for primary cannulation to reduce pancreatitis (moderate-quality evidence, strong recommendation) and defines difficult cannulation as more than five papillary contacts, more than five minutes, or more than one unintended pancreatic duct cannulation. It does not specify wire diameter.

Patients with an intact papilla were randomised to a 0.025-inch or 0.035-inch guidewire for primary cannulation. Primary cannulation before difficult-cannulation criteria were met was 47.7% vs 43.1% (risk difference +4.6%, 95% CI −12.2 to +21.1), which met the trial’s non-inferiority criterion. Final cannulation was 96.9% in both arms. Post-ERCP pancreatitis was 9.2% vs 16.9% (p = 0.30). With the 0.025-inch wire, experienced endoscopists had higher primary success than fellows (67.9% vs 32.4%), but the wire-by-experience interaction was not significant (p = 0.16).

Earlier randomised evidence points the same way. Three previous RCTs, about 1,080 patients between them, found no difference in cannulation success or pancreatitis. The largest, a nine-centre Asia-Pacific trial of 710 patients (Bassan et al., Gastrointest Endosc 2018;87:1454–1460, PMID 29317269), reported primary cannulation of 80.7% vs 80.3% and pancreatitis of 7.8% vs 9.3%. A 269-patient Japanese trial (Kitamura et al., World J Gastroenterol 2015;21:9182–9188, PMID 26290646) found 80.7% vs 86.3% primary success (P = 0.226) and pancreatitis of 2.8% vs 2.5%. A 100-patient Finnish trial of a thin wire with a thin sphincterotome (Halttunen and Kylänpää, Surg Endosc 2013;27:1662–1667, PMID 23239304) found no difference in primary cannulation and two pancreatitis cases in total, one per arm. I did not identify a meta-analysis dedicated to wire calibre.

The pancreatitis benefit comes from using a wire. The Cochrane review of 15 RCTs and 4,426 participants (Tse et al., Cochrane Database Syst Rev 2022;3:CD009662, PMID 35349163) found that guidewire-assisted cannulation probably reduces pancreatitis against contrast-assisted cannulation (RR 0.51, 95% CI 0.36 to 0.72, moderate certainty), and may modestly raise primary cannulation success (low certainty). Nothing in the calibre trials suggests that diameter adds to that effect.

Three cautions. The confidence interval is wide, so “non-inferior” should be read with care. The pancreatitis difference is not significant and the trial was not powered for it. And the experience comparison is a planned subgroup, not a randomised comparison.

Clinical bottom line: Wire calibre did not change cannulation success. Operator experience did. The pancreatitis difference is not significant, and the trial was not powered for it.

Primary literature identified via PubMed systematic search. Broader clinical context, including identification of contemporaneous trials, meta-analyses, and guideline positions, verified through structured evidence synthesis. All references independently confirmed via PubMed prior to inclusion.

ALSO PUBLISHED — SEPTEMBER 2026

1. [EUS-GBD] Primary EUS-GBD and conversion after PTGBD both worked in surgically unfit patients, n=239

Procedural success 95.6% (primary, n=180) vs 93.2% (conversion, n=59); early adverse events 10.6% vs 11.9%. Prior PTGBD did not appear to compromise EUS-GBD. Retrospective, so selection bias applies.

Kim SH et al. · Endoscopy 2026 · doi:10.1055/a-2951-4600 · PMID 42735722

2. [EUS-BD / EUS-GE] Hepaticogastrostomy had less stent dysfunction than choledochoduodenostomy when EUS-GE treats concomitant gastric outlet obstruction

Systematic review and meta-analysis: stent dysfunction 45.1% with choledochoduodenostomy vs 10.9% with hepaticogastrostomy (RR 4.42). Consistent with ESGE 2026, which suggests hepaticogastrostomy where a duodenal stricture is present.

Spadaccini M et al. · United European Gastroenterol J 2026 · doi:10.1002/ueg2.70265 · PMID 42713827

3. [EUS-BD] EUS-BD in large-volume ascites carries a high adverse-event risk, and perihepatic ascites thickness helps select patients

Multicentre retrospective: perihepatic ascites thickness of 15.5 mm or more predicted intra-abdominal adverse events (AUC 0.82). 32.6% died in hospital, median post-procedural survival 1.8 months.

Koga et al. · Gut Liver 2026 · doi:10.5009/gnl260042 · PMID 42682268

4. [EUS-GE] EUS-GE learning curve plateaus at about 20 procedures per centre

Bicentric retrospective, n=96. A pragmatic benchmark for credentialing and for how many cases a unit needs before expecting stable results.

Toppeta et al. · Endosc Ultrasound 2026 · doi:10.1097/eus.0000000000000221 · PMID 42751695

5. [ERCP / ampullary · guideline] AGA clinical practice update on ampullary neoplasms: 15 best-practice advice statements

Expert review. Surveillance beyond five years after resection should be individualised by health and life expectancy; patients with high-grade dysplasia, incomplete resection or suspected malignancy should go to a multidisciplinary team.

Barakat et al. · Clin Gastroenterol Hepatol 2026 · doi:10.1016/j.cgh.2026.07.013 · PMID 42720640

6. [ERCP / pancreatitis] Fatty pancreas appears to amplify the pancreatitis risk of pancreatic manipulation during ERCP

Multicentre retrospective, n=679: fatty pancreas on CT in 27.0%, pancreatitis in 9.9%. Adjusted OR 2.17 for fatty pancreas and 1.53 per manipulation-score point; interaction OR 1.62 (1.07 to 2.46), but the categorical interaction was not significant (P = 0.067). Hypothesis-generating.

Liu Y et al. · Dig Dis Sci 2026 · doi:10.1007/s10620-026-10247-7 · PMID 42758387

7. [EUS / FNB] EUS-FNB changed management in 8.2% of radiologically suspected pancreatic neuroendocrine tumours

Management changed in 12 patients: different tumour type or added high-risk feature (5), different grade (4), no malignancy (3). Argues for systematic rather than selective biopsy.

González-Abós et al. · J Dig Dis 2026 · doi:10.1111/1751-2980.70069 · PMID 42687717

8. [ERCP] Sphincterotomy before biliary stenting reduced pancreatitis only where pancreatic cancer prevalence was low

Systematic review and meta-analysis of 6 RCTs, n=1,215: pancreatitis reduction (RR 0.23) was confined to low-prevalence populations. Relevant to metal-stent drainage in suspected pancreatic cancer.

Meine et al. · J Gastroenterol Hepatol 2026 · doi:10.1111/jgh.70714 · PMID 42694002

9. [EUS / sustainability] EUS had a lower carbon footprint than MRCP for intermediate-likelihood bile duct stones

Prospective study: choosing EUS for 108 patients saved 1,552 kg CO2e. The advantage narrowed and could reverse on low-carbon electricity grids, which matters for the UK as the grid decarbonises.

Rughwani et al. · Clin Transl Gastroenterol 2026 · doi:10.14309/ctg.0000000000001098 · PMID 42709924

10. [ERCP] Primary needle-knife fistulotomy in patients at high risk of post-ERCP pancreatitis: outcomes varied by operator experience

Prospective non-randomised multicentre pilot, n=139: adverse events 13.6%, 4.2% and 0% across three operator-experience groups (P = .012). Pilot design, no comparator arm.

Ko et al. · Dig Dis Sci 2026 · doi:10.1007/s10620-026-10219-x · PMID 42809068


Scoring note: papers are ranked with a five-domain editorial tool (study design, clinical relevance, journal, novelty, UK/Ireland author bonus) informed by SORT and GRADE principles. It is a relative ranking tool, not a validated instrument. The full scoring table and exclusion log are on the website.

© UKIEUS 2026 · Editorial commentary by Dr Venkat Mahesh, MRCP, FEBGH · Paper titles and abstracts cited from PubMed with DOI attribution; no copyrighted full text reproduced · For educational use only · www.ukieus.co.uk

Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments